GlassScriptPhysician profile
Adelina M Dunn
NPI 1689629438
$5,901.60
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,734 · 2020: $1,866 · 2021: $1,542 · 2022: $760.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $897.05 | 2019-2022 | |
| Glaxosmithkline, LLC. | $879.75 | 2019-2022 | |
| Lilly USA, LLC | $507.13 | 2019-2021 | |
| Novo Nordisk INC | $414.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.59 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $291.51 | 2019-2022 | |
| Abbvie INC. | $277.20 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.47 | 2019-2021 | |
| Amarin Pharma, INC. | $263.92 | 2019-2022 | |
| Amgen INC. | $261.79 | 2019-2022 | |
| Pfizer INC. | $200.41 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $171.14 | 2019-2021 | |
| Astellas Pharma US INC | $145.77 | 2019-2022 | |
| Allergan, INC. | $131.71 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $112.54 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $98.81 | 2021 | |
| Tactile Systems Technology INC | $79.73 | 2019 | |
| Esperion Therapeutics, INC. | $68.26 | 2021-2022 | |
| Aytu Biopharma, INC. | $64.56 | 2019-2020 | |
| Eisai INC. | $62.66 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $57.17 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.80 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $31.65 | 2020-2021 | |
| Zyla Life Sciences, INC. | $25.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.31 | 2019 | |
| Bausch Health US, LLC | $15.90 | 2021 | |
| Philips North America LLC | $15.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.17 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.16 | 2019 | |
| Iroko Pharmaceuticals, LLC | $11.75 | 2019 | |
| Orexo US, INC. | $11.27 | 2019 | |
| Assertio Therapeutics, INC. | $10.96 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adelina Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.